Cargando…

Targeting parallel bypass signaling to combat adaptive resistance to BRAF inhibition in colorectal cancer

Detalles Bibliográficos
Autores principales:	Gao, Chenxi, Hu, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978442/ https://www.ncbi.nlm.nih.gov/pubmed/29854868 http://dx.doi.org/10.18632/oncoscience.401

Ejemplares similares

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
por: Wang, Beike, et al.
Publicado: (2021)

BRAF Mutations and Resistance of Non-Small Cell Lung Cancer to BRAF-Targeted Therapies Using Liquid Biopsy
por: Li, Ming, et al.
Publicado: (2021)

Cell hierarchies in colorectal cancer: focus on APC and BRAF
por: Morkel, Markus, et al.
Publicado: (2015)

Combination drug development in BRAF mutant colorectal cancer
por: Lam, Michael, et al.
Publicado: (2018)

Combating resistance to DNA damaging agents
por: Choi, Jung-Suk, et al.
Publicado: (2018)

COMBAR – Combatting anthelmintic resistance in ruminants
por: Charlier, Johannes, et al.
Publicado: (2023)

Targeting mutant BRAF in colorectal cancer
por: Carroll, David, et al.
Publicado: (2013)

Targeting BRAF and RAS in Colorectal Cancer
por: Bellio, Helene, et al.
Publicado: (2021)

Does BRAF Mutation and Extracellular Signal Regulated Kinase Expression in Patients With Colorectal Cancer Have Any Prognostic Significance?
por: Baek, Moo Jun
Publicado: (2015)

Targeting BRAF-mutant tumours with TGFBR1 inhibitors
por: Spender, Lindsay C, et al.
Publicado: (2017)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Combating Antimicrobial Resistance: Going Beyond New Antibiotics
por: Jhaveri, Ravi
Publicado: (2020)

Targeting RIPK1,2,3 to combat inflammation
por: Bullock, Alex N., et al.
Publicado: (2015)

Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models
por: Tran, Khanh B., et al.
Publicado: (2022)

Adapting a Phage to Combat Phage Resistance
por: Laanto, Elina, et al.
Publicado: (2020)

Antimicrobial resistance needs to be combated at primary levels of prevention by nurses
por: Oerther, Sarah, et al.
Publicado: (2020)

Thrombosis and fibrosis: mutually inclusive targets to combat in COVID-19
por: Agirbasli, Mehmet
Publicado: (2021)

Combating cough
por: Morice, Alyn H
Publicado: (2016)

The Combat Deepens
Publicado: (1883)

The Non-Combatants
Publicado: (1917)

Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma
por: Saei, Azad, et al.
Publicado: (2019)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells
por: Goulielmaki, Maria, et al.
Publicado: (2016)

Molecular targeted therapy of BRAF-mutant colorectal cancer
por: Ducreux, Michel, et al.
Publicado: (2019)

Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance
por: Harrison, Peter T., et al.
Publicado: (2018)

Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma
por: Ades, Felipe, et al.
Publicado: (2012)

BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling
por: Vin, Harina, et al.
Publicado: (2013)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

An amino-terminal BRAF deletion accounting for acquired resistance to RAF/EGFR inhibition in colorectal cancer
por: Tung, Jack K., et al.
Publicado: (2020)

New insights in melanoma resistance to BRAF inhibitors: a role for microRNAs
por: Díaz-Martínez, Marta, et al.
Publicado: (2018)

Combating Kinetoplastid diseases
por: Dávila, Alberto MR, et al.
Publicado: (2002)

Combating Kidney Fibrosis
por: Kanasaki, Keizo, et al.
Publicado: (2014)

Communication combats hesitancy
por: The Lancet Rheumatology
Publicado: (2021)

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance
por: Sullivan, Ryan J., et al.
Publicado: (2011)

Melatonin synergizes BRAF‐targeting agent dabrafenib for the treatment of anaplastic thyroid cancer by inhibiting AKT/hTERT signalling
por: Liao, Yina, et al.
Publicado: (2020)

Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition
por: Hardeman, Keisha N., et al.
Publicado: (2017)

Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas
por: Roller, Devin G., et al.
Publicado: (2015)

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal tumors
por: Ruiz-Saenz, Ana, et al.
Publicado: (2023)

Proteogenomics Reveals Perturbed Signaling Networks in Malignant Melanoma Cells Resistant to BRAF Inhibition
por: Schmitt, Marisa, et al.
Publicado: (2021)

Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells
por: Lamichhane, Astha, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_72sppdlii4hlnii03tplf0ugnj